208 related articles for article (PubMed ID: 21535451)
1. Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates from AIDS patients in Kenya.
Mdodo R; Moser SA; Jaoko W; Baddley J; Pappas P; Kempf MC; Aban I; Odera S; Jolly P
Mycoses; 2011 Sep; 54(5):e438-42. PubMed ID: 21535451
[TBL] [Abstract][Full Text] [Related]
2. Antifungal drug susceptibility of Cryptococcus neoformans from clinical sources in Nairobi, Kenya.
Bii CC; Makimura K; Abe S; Taguchi H; Mugasia OM; Revathi G; Wamae NC; Kamiya S
Mycoses; 2007 Jan; 50(1):25-30. PubMed ID: 17302744
[TBL] [Abstract][Full Text] [Related]
3. Comparative analysis of the Vitek 2 antifungal susceptibility system and E-test with the CLSI M27-A3 broth microdilution method for susceptibility testing of Indian clinical isolates of Cryptococcus neoformans.
Tewari A; Behera B; Mathur P; Xess I
Mycopathologia; 2012 Jun; 173(5-6):427-33. PubMed ID: 22354778
[TBL] [Abstract][Full Text] [Related]
4. Genotyping and antifungal susceptibility testing of Cryptococcus neoformans isolates from Cameroonian HIV-positive adult patients.
Bertout S; Drakulovski P; Kouanfack C; Krasteva D; Ngouana T; Dunyach-Rémy C; Dongtsa J; Aghokeng A; Delaporte E; Koulla-Shiro S; Reynes J; Mallié M
Clin Microbiol Infect; 2013 Aug; 19(8):763-9. PubMed ID: 23033854
[TBL] [Abstract][Full Text] [Related]
5. Comparative antifungal susceptibility analyses of Cryptococcus neoformans VNI and Cryptococcus gattii VGII from the Brazilian Amazon Region by the Etest, Vitek 2, and the Clinical and Laboratory Standards Institute broth microdilution methods.
Nishikawa MM; Almeida-Paes R; Brito-Santos F; Nascimento CR; Fialho MM; Trilles L; Morales BP; da Silva SA; Santos W; Santos LO; Fortes ST; Cardarelli-Leite P; Lázera MDS
Med Mycol; 2019 Oct; 57(7):864-873. PubMed ID: 30657975
[TBL] [Abstract][Full Text] [Related]
6. Molecular epidemiology and in vitro antifungal susceptibility testing of 108 clinical Cryptococcus neoformans sensu lato and Cryptococcus gattii sensu lato isolates from Denmark.
Hagen F; Hare Jensen R; Meis JF; Arendrup MC
Mycoses; 2016 Sep; 59(9):576-84. PubMed ID: 27061834
[TBL] [Abstract][Full Text] [Related]
7. In vitro antifungal susceptibility profiles and genotypes of 308 clinical and environmental isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii serotype B from north-western India.
Chowdhary A; Randhawa HS; Sundar G; Kathuria S; Prakash A; Khan Z; Sun S; Xu J
J Med Microbiol; 2011 Jul; 60(Pt 7):961-967. PubMed ID: 21393452
[TBL] [Abstract][Full Text] [Related]
8. Antifungal susceptibility testing with YeastONE™ is not predictive of clinical outcomes of Cryptococcus neoformans var. grubii fungemia.
Yang JH; Huang PY; Cheng CW; Shie SS; Lin ZF; Yang LY; Lee CH; Wu TS
Med Mycol; 2021 Nov; 59(11):1114-1121. PubMed ID: 34374784
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Etests and Vitek 2 ® to broth microdilution for the susceptibility testing of Cryptococcus neoformans.
Mahabeer Y; Chang CC; Naidu D; Dorasamy A; Lewin S; Ndung'u T; Moosa MY; French M; Mlisana K; Coovadia Y
Diagn Microbiol Infect Dis; 2014 Dec; 80(4):294-8. PubMed ID: 25277745
[TBL] [Abstract][Full Text] [Related]
10. Antifungal susceptibilities of clinical and environmental isolates of Cryptococcus neoformans in Goiânia city, Goiás, Brazil.
Souza LK; Fernandes Ode F; Kobayashi CC; Passos XS; Costa CR; Lemos JA; Souza-Júnior AH; Silva Mdo R
Rev Inst Med Trop Sao Paulo; 2005; 47(5):253-6. PubMed ID: 16302107
[TBL] [Abstract][Full Text] [Related]
11. Serotyping of Cryptococcus neoformans strains isolated from clinical specimens in Thailand and their susceptibility to various antifungal agents.
Poonwan N; Mikami Y; Poosuwan S; Boon-Long J; Mekha N; Kusum M; Yazawa K; Tanaka R; Nishimura K; Konyama K
Eur J Epidemiol; 1997 Apr; 13(3):335-40. PubMed ID: 9258534
[TBL] [Abstract][Full Text] [Related]
12. Antifungal susceptibilities of Cryptococcus species complex isolates from AIDS and non-AIDS patients in Southeast China.
Li M; Liao Y; Chen M; Pan W; Weng L
Braz J Infect Dis; 2012; 16(2):175-9. PubMed ID: 22552461
[TBL] [Abstract][Full Text] [Related]
13. In vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and blood from patients in Serbia.
Trpković A; Pekmezović M; Barać A; Crnčević Radović L; Arsić Arsenijević V
J Mycol Med; 2012 Sep; 22(3):243-8. PubMed ID: 23518082
[TBL] [Abstract][Full Text] [Related]
14. Interactions between triazoles and amphotericin B against Cryptococcus neoformans.
Barchiesi F; Schimizzi AM; Caselli F; Novelli A; Fallani S; Giannini D; Arzeni D; Di Cesare S; Di Francesco LF; Fortuna M; Giacometti A; Carle F; Mazzei T; Scalise G
Antimicrob Agents Chemother; 2000 Sep; 44(9):2435-41. PubMed ID: 10952592
[TBL] [Abstract][Full Text] [Related]
15. Antifungal susceptibility of clinical and environmental Cryptococcus neoformans and Cryptococcus gattii isolates in Jabalpur, a city of Madhya Pradesh in Central India.
Gutch RS; Nawange SR; Singh SM; Yadu R; Tiwari A; Gumasta R; Kavishwar A
Braz J Microbiol; 2015; 46(4):1125-33. PubMed ID: 26691471
[TBL] [Abstract][Full Text] [Related]
16. Cryptococcus neoformans and C. gattii isolates from both HIV-infected and uninfected patients: antifungal susceptibility and outcome of cryptococcal disease.
Nascimento E; Vitali LH; Kress MRVZ; Martinez R
Rev Inst Med Trop Sao Paulo; 2017; 59():e49. PubMed ID: 28793019
[TBL] [Abstract][Full Text] [Related]
17. Rates of antifungal resistance among Spanish clinical isolates of Cryptococcus neoformans var. neoformans.
Perkins A; Gomez-Lopez A; Mellado E; Rodriguez-Tudela JL; Cuenca-Estrella M
J Antimicrob Chemother; 2005 Dec; 56(6):1144-7. PubMed ID: 16282208
[TBL] [Abstract][Full Text] [Related]
18. Serotypes of clinical cerebrospinal fluid Cryptococcus neoformans isolates from southern Taiwan and their in vitro susceptibilities to amphotericin B, fluconazole, and voriconazole.
Chang WN; Huang CR; Lei CB; Lee PY; Chien CC; Chang HW; Chang CS; Lu CH
Jpn J Infect Dis; 2004 Jun; 57(3):113-5. PubMed ID: 15218221
[TBL] [Abstract][Full Text] [Related]
19. Molecular epidemiology and antifungal susceptibility of Cryptococcus neoformans isolates from Ugandan AIDS patients.
Pfaller M; Zhang J; Messer S; Tumberland M; Mbidde E; Jessup C; Ghannoum M
Diagn Microbiol Infect Dis; 1998 Nov; 32(3):191-9. PubMed ID: 9884835
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of antifungal combination against Cryptococcus spp.
Reichert-Lima F; Busso-Lopes AF; Lyra L; Peron IH; Taguchi H; Mikami Y; Kamei K; Moretti ML; Schreiber AZ
Mycoses; 2016 Sep; 59(9):585-93. PubMed ID: 27135278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
